Enrico T.
- Country
- Italy
- Department
- Sezione di Ematologia e Immunologia Clinica
Research Overview
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy D - Relapsed/Refractory Hairy Cell Leukemia (HCL)
Data & Insights
Has run more than one trial at 28 of 41 partner sites.
Specializations
Rare B-Cell Malignancies
This investigator specializes in treating rare and challenging forms of B-cell malignancies, with particular expertise in developing therapeutic approaches for conditions that have proven resistant to conventional treatments.
- Burkitt Lymphoma management
- Waldenstrom Macroglobulinemia treatment
- Richter Transformation therapy
Hairy Cell Leukemia
The investigator demonstrates significant focus on advancing treatment options for Hairy Cell Leukemia, exploring both traditional and innovative therapeutic approaches.
- Novel targeted therapies including BRAF inhibitors
- Chemotherapy-free treatment alternatives
- Combination therapy strategies
Classical Hodgkin Lymphoma
The investigator pursues innovative treatment combinations for relapsed/refractory classical Hodgkin lymphoma, incorporating modern therapeutic agents.
- JAK1/2 inhibitor combinations
- Immunotherapy applications
- Treatment resistance strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.